Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.37 USD
-0.03 (-2.14%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $1.38 +0.01 (0.73%) 4:18 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 43 | 90 | 150 | 229 | 147 |
Receivables | 39 | 40 | 51 | 67 | 39 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 22 | 38 | 61 | 116 |
Other Current Assets | 20 | 33 | 33 | 15 | 7 |
Total Current Assets | 118 | 185 | 272 | 371 | 310 |
Net Property & Equipment | 4 | 5 | 7 | 9 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 95 | 131 | 163 | 199 | 346 |
Deposits & Other Assets | 12 | 5 | 50 | 38 | 76 |
Total Assets | 242 | 356 | 526 | 644 | 771 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 18 | 34 | 41 | 39 |
Current Portion Long-Term Debt | 18 | 32 | 98 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 68 | 76 | 104 | 131 | 129 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 4 | 21 | 15 | 40 |
Total Current Liabilities | 100 | 130 | 256 | 187 | 208 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 43 | 43 | 21 | 25 | 33 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 17 | 34 | 0 | 96 | 76 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 103 | 115 | 137 | 63 | 32 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 272 | 351 | 449 | 397 | 376 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,578 | 1,562 | 1,537 | 1,425 | 1,189 |
Retained Earnings | -1,609 | -1,557 | -1,460 | -1,178 | -794 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -31 | 5 | 76 | 248 | 395 |
Total Liabilities & Shareholder's Equity | 242 | 356 | 526 | 644 | 771 |
Total Common Equity | -31 | 5 | 76 | 248 | 395 |
Shares Outstanding | 188.30 | 183.90 | 174.90 | 144.50 | 118.90 |
Book Value Per Share | -0.16 | 0.03 | 0.44 | 1.71 | 3.32 |
Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 40 | 42 | 43 | 47 | 54 |
Receivables | 30 | 27 | 39 | 23 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 24 | 26 | 16 | 18 | 21 |
Other Current Assets | 19 | 19 | 20 | 22 | 24 |
Total Current Assets | 112 | 113 | 118 | 110 | 118 |
Net Property & Equipment | 3 | 3 | 4 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 77 | 86 | 95 | 104 | 113 |
Deposits & Other Assets | 18 | 12 | 12 | 4 | 3 |
Total Assets | 220 | 225 | 242 | 235 | 254 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 12 | 15 | 9 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 18 | 8 | 24 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 54 | 54 | 68 | 63 | 56 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 43 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 107 | 66 | 100 | 80 | 92 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 43 | 43 | 43 | 43 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 38 | 30 | 17 | 35 | 18 |
Non-Current Capital Leases | 6 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 102 | 103 | 107 | 115 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 254 | 253 | 272 | 274 | 281 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,602 | 1,600 | 1,578 | 1,570 | 1,568 |
Retained Earnings | -1,636 | -1,627 | -1,609 | -1,610 | -1,595 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -34 | -27 | -31 | -39 | -27 |
Total Liabilities & Shareholder's Equity | 220 | 225 | 242 | 235 | 254 |
Total Common Equity | -34 | -27 | -31 | -39 | -27 |
Shares Outstanding | 209.60 | 209.30 | 188.30 | 188.30 | 185.90 |
Book Value Per Share | -0.16 | -0.13 | -0.16 | -0.21 | -0.14 |